Billiontoone (NASDAQ:BLLN) Insider Shan Riku Sakakibara Sells 8,000 Shares

Billiontoone, Inc. (NASDAQ:BLLN) insider Shan Riku Sakakibara sold 8,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 24th. The stock was sold at an average price of $110.00, for a total value of $880,000.00. Following the completion of the transaction, the insider directly owned 208,000 shares in the company, valued at approximately $22,880,000. This represents a 3.70% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Shan Riku Sakakibara also recently made the following trade(s):

• On Monday, June 8th, Shan Riku Sakakibara sold 8,000 shares of Billiontoone stock. The shares were sold at an average price of $98.22, for a total transaction of $785,760.00.

Billiontoone Trading Up 5.3%

Shares of BLLN stock opened at $118.17 on Friday. The company has a market cap of $5.43 billion and a PE ratio of 214.85. The company has a debt-to-equity ratio of 0.18, a current ratio of 10.92 and a quick ratio of 10.58. The stock’s 50 day simple moving average is $92.57 and its two-hundred day simple moving average is $87.32. Billiontoone, Inc. has a 1 year low of $61.96 and a 1 year high of $138.70.

Billiontoone (NASDAQ:BLLN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.01 by $0.33. The company had revenue of $108.39 million during the quarter, compared to the consensus estimate of $95.81 million. The firm’s quarterly revenue was up 83.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.39) earnings per share. Research analysts predict that Billiontoone, Inc. will post 0.93 earnings per share for the current year.

Analyst Ratings Changes

BLLN has been the topic of several recent analyst reports. BTIG Research reduced their price target on Billiontoone from $140.00 to $130.00 and set a “buy” rating on the stock in a report on Thursday, May 7th. Wells Fargo & Company dropped their price objective on shares of Billiontoone from $110.00 to $90.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 5th. JPMorgan Chase & Co. boosted their target price on shares of Billiontoone from $120.00 to $125.00 and gave the stock an “overweight” rating in a report on Thursday, May 7th. Wall Street Zen raised Billiontoone from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Finally, Weiss Ratings raised shares of Billiontoone from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $125.29.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Rossby Financial LCC acquired a new stake in shares of Billiontoone in the fourth quarter valued at approximately $25,000. Wells Fargo & Company MN acquired a new stake in shares of Billiontoone during the 4th quarter worth approximately $76,000. Smartleaf Asset Management LLC acquired a new position in Billiontoone in the fourth quarter valued at approximately $80,000. Nano Cap New Millennium Growth Fund L P purchased a new position in Billiontoone in the fourth quarter worth approximately $82,000. Finally, Renaissance Capital LLC purchased a new stake in Billiontoone in the fourth quarter valued at $201,000.

Billiontoone Company Profile

BillionToOne (NASDAQ: BLLN) is a molecular diagnostics company that develops and commercializes high-precision genetic testing solutions based on single-molecule counting technology. The company’s platform is designed to detect and quantify rare genetic variants and chromosomal abnormalities from cell-free DNA, with a primary focus on applications in prenatal screening and other clinical genetic tests where sensitivity and specificity at very low allele fractions are critical.

BillionToOne’s offerings center on assay development and clinical testing workflows that enable non-invasive prenatal testing (NIPT) and targeted molecular diagnostics.